Proof of Efficacy Is Not Enough: Contemporary Management of Patients With Metastatic Renal Cell Carcinoma With Targeted Therapy

被引：1
作者：
Sun, Maxine [1 ]
Bianchi, Marco [1 ,2 ]
Hansen, Jens [1 ,3 ]
Quoc-Dien Trinh [1 ,4 ]
Karakiewicz, Pierre I. [1 ]
机构：
[1] Univ Montreal, Ctr Hlth, Montreal, PQ, Canada
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Prostate Canc Ctr Hamburg Eppendorf, Martini Klin, Hamburg, Germany
[4] Henry Ford Hosp, Vattikuti Urol Inst, Detroit, MI 48202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 31期
关键词：
INTERFERON-ALPHA; DOUBLE-BLIND; SUNITINIB; SURVIVAL;
D O I：
10.1200/JCO.2012.43.7376
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3901 / 3901
页数：1
相关论文
共 14 条
  • [1] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Escudier, Bernard
    Pluzanska, Anna
    Koralewski, Piotr
    Ravaud, Alain
    Bracarda, Sergio
    Szczylik, Cezary
    Chevreau, Christine
    Filipek, Marek
    Melichar, Bohuslav
    Bajetta, Emilio
    Gorbunova, Vera
    Bay, Jacques-Olivier
    Bodrogi, Istvan
    Jagiello-Gruszfeld, Agnieszka
    Moore, Nicola
    [J]. LANCET, 2007, 370 (9605) : 2103 - 2111
  • [2] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
  • [3] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
    Escudier, Bernard
    Bellmunt, Joaquim
    Negrier, Sylvie
    Bajetta, Emilio
    Melichar, Bohuslav
    Bracarda, Sergio
    Ravaud, Alain
    Golding, Sophie
    Jethwa, Sangeeta
    Sneller, Vesna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2144 - 2150
  • [4] Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
    Motzer, RJ
    Mazumdar, M
    Bacik, J
    Berg, W
    Amsterdam, A
    Ferrara, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2530 - 2540
  • [5] Motzer RJ, 2012, J CLIN ONCOL, V30, p277s
  • [6] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Gruenwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Urbanowitz, Gladys
    Berg, William J.
    Kay, Andrea
    Lebwohl, David
    Ravaud, Alain
    [J]. LANCET, 2008, 372 (9637) : 449 - 456
  • [7] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Rixe, Olivier
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Kim, Sindy T.
    Chen, Isan
    Bycott, Paul W.
    Baum, Charles M.
    Figlin, Robert A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 115 - 124
  • [8] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Pili, Roberto
    Bjarnason, Georg A.
    Garcia-del-Muro, Xavier
    Sosman, Jeffrey A.
    Solska, Ewa
    Wilding, George
    Thompson, John A.
    Kim, Sindy T.
    Chen, Isan
    Huang, Xin
    Figlin, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3584 - 3590
  • [9] Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
    Nosov, Dmitry A.
    Esteves, Brooke
    Lipatov, Oleg N.
    Lyulko, Alexei A.
    Anischenko, A. A.
    Chacko, Raju T.
    Doval, Dinesh C.
    Strahs, Andrew
    Slichenmyer, William J.
    Bhargava, Pankaj
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) : 1678 - 1685
  • [10] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Rini, Brian I.
    Escudier, Bernard
    Tomczak, Piotr
    Kaprin, Andrey
    Szczylik, Cezary
    Hutson, Thomas E.
    Michaelson, M. Dror
    Gorbunova, Vera A.
    Gore, Martin E.
    Rusakov, Igor G.
    Negrier, Sylvie
    Ou, Yen-Chuan
    Castellano, Daniel
    Lim, Ho Yeong
    Uemura, Hirotsugu
    Tarazi, Jamal
    Cella, David
    Chen, Connie
    Rosbrook, Brad
    Kim, Sinil
    Motzer, Robert J.
    [J]. LANCET, 2011, 378 (9807) : 1931 - 1939
12